Entrada Therapeutics (TRDA) Asset Utilization Ratio (2023 - 2026)

Entrada Therapeutics' Asset Utilization Ratio history runs 4 years deep, the most recent figure standing at 0.02 for Q1 2026.

• In Q1 2026, Asset Utilization Ratio fell 95.27% year-over-year to 0.02; the TTM figure through Mar 2026 stood at 0.02 (down 95.27% YoY), while the FY2025 annual figure was 0.06, down 86.71% from the prior year.
• Asset Utilization Ratio was 0.02 for Q1 2026 at Entrada Therapeutics, down from 0.06 in the prior quarter.
• In the past five years, Asset Utilization Ratio ranged from a high of 0.44 in Q2 2024 to a low of 0.02 in Q1 2026.
• Historically, Asset Utilization Ratio has averaged 0.22 across 4 years, with a median of 0.18 in 2023.
• The sharpest annual moves came in 2024 and 2026: Asset Utilization Ratio surged 389.05% in 2024, then tumbled 95.27% in 2026.
• A 4-year view of Asset Utilization Ratio shows it stood at 0.27 in 2023, then jumped by 44.23% to 0.39 in 2024, then sank by 83.5% to 0.06 in 2025, then sank by 74.98% to 0.02 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.02 (Q1 2026), 0.06 (Q4 2025), and 0.14 (Q3 2025), per Business Quant data.